Techniclone International Corp.
The company said Thursday that a “major shareholder” agreed to buy 1 million of its shares for $1,500,000.
In a press release, the Tustin company said it will use proceeds from the sale to complete the necessary steps to submit its Food and Drug Administration application for permission to conduct Phase 3 clinical trials with its LYM-1 therapeutic antibody.
